<DOC>
	<DOCNO>NCT02662348</DOCNO>
	<brief_summary>This phase I trial investigate safety possible side effect bi-specific antibody arm T-cell therapy give together low-dose IL-2 treating patient Her2-positive neoplasm digestive system . Expanded autologues T cell coat bi-specific antibody , anti-CD3 anti-human epidermal growth factor receptor 2 ( HER2 ) , may stimulate immune system different way stop tumor cell grow . Interleukin-2 may stimulate white blood cell kill tumor cell .</brief_summary>
	<brief_title>T Cell Mediated Adaptive Therapy Her2-positive Neoplasms Digestive System</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Perform phase I clinical trial clearly define toxicity profile IV HER2Bi arm T cell patient neoplasms digestive system . SECONDARY OBJECTIVES : I . Evaluate phenotype , cytokine profile tumor marker , cytotoxicity direct laboratory Her2 positive cancer cell line . II . Evaluate clinical symptom sign , clinical response , image examination pretherapy post-treatment , cytokine profile tumor marker serum treatment , time progression , overall survival . OUTLINE : This safety study IV infuse HER2Bi-armed activate T cell . Patients receive HER2Bi arm T cell IV weekly 4 week . Patients also receive low-dose Interleukin subcutaneously ( SC ) daily begin 3 day first HER2Bi arm T cell infusion . Treatment continue absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>1 . Patient Her2positive neoplasms digestive system : IHC 3+ 2 . Clinical staging : Phase III 3 . Ages : &lt; 65 4 . Expected survival time : &gt; 1 year 5 . Quality Life : &gt; 60 6 . The function important organ ( heart , liver , lung , kidney etc . ) normal 7 . The volunteer inform consent Exclusion criterion : 1 . Patient Her2negative neoplasms digestive system 2 . Hepatic renal dysfunction 3 . Cardiopulmonary insufficiency 4 . Mental disorder 5 . Allergic condition 6 . With malignant tumor 7 . Lactating woman 8 . Patients infection receive chemotherapy past two week 9 . Patient autoimmune disease use immunosuppressive drug 10 . Patient organ transplantation long term use immunosupresive drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>